Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 1,000 Shares of Stock

Key Points

• Christopher Causey, Director at United Therapeutics, sold 1,000 shares at an average price of $440.00, amounting to $440,000, reducing his position by 17.05% to a total of 4,865 shares.
• The stock experienced a drop of $13.33 during trading, landing at $425.42, with a 12-month range from $266.98 to $442.01.
• Analysts have mixed recommendations, with price targets ranging from $330.00 to $564.00, reflecting diverse opinions on the stock's future performance.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Christopher Causey sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $440.00, for a total value of $440,000.00. Following the transaction, the director owned 4,865 shares in the company, valued at $2,140,600. This represents a 17.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Christopher Causey also recently made the following trade(s):

• On Tuesday, September 2nd, Christopher Causey sold 3,000 shares of United Therapeutics stock. The stock was sold at an average price of $423.21, for a total value of $1,269,630.00.

United Therapeutics Stock Performance

United Therapeutics stock traded down $13.33 during mid-day trading on Thursday, reaching $425.42. 966,491 shares of the company were exchanged, compared to its average volume of 584,076. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $442.01. The firm's 50-day simple moving average is $337.52 and its two-hundred day simple moving average is $313.10. The firm has a market cap of $19.19 billion, a PE ratio of 16.61, a price-to-earnings-growth ratio of 6.62 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same period in the previous year, the business posted $5.85 earnings per share. The firm's revenue was up 11.7% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on UTHR shares. Bank of America increased their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Morgan Stanley dropped their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Finally, Jefferies Financial Group increased their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $438.85.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares in the last quarter. SVB Wealth LLC bought a new stake in shares of United Therapeutics in the first quarter worth $32,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after buying an additional 85 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.